# BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

> **NCT00326495** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** BAY 43-9006

## Key facts

- **NCT ID:** NCT00326495
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-10
- **Primary completion:** 2014-11-05
- **Final completion:** 2014-11-07
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326495, "BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00326495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*